TripSit home
Contraindications Closed-angle glaucoma, phaeochromocytoma, asymmetric septal hypertrophy (idiopathic hypertrophic subaortic stenosis), concomitant or recent (previous 14 days) monoamine oxidase inhibitor (MAOI) therapy, general anaesthesia with halogenated hydrocarbons (particularly halothane), tachyarrhythmias or ventricular fibrillation, and hypersensitivity to ephedrine or other stimulants.
Chemical Name

Ephedrine

Categories

Stimulant, Habit-forming

Summary

Ephedrine is a sympathomimetic amine commonly used as a stimulant, concentration aid, decongestant, appetite suppressant, and to treat hypotension associated with anaesthesia. A methamphetamine analogue and commonly used in the production of methamphetamine.

Adverse-effects

Tachycardia, cardiac arrhythmias, angina pectoris, vasoconstriction with hypertension, flushing, sweating, acne vulgaris, nausea, decreased urination, difficulty urinating, restlessness, confusion, insomnia, mild euphoria, mania/hallucinations, delusions, formication, dyspnea, pulmonary edema, dizziness, headache, tremor, hyperglycemic reactions, and dry mouth

Contraindications

Closed-angle glaucoma, phaeochromocytoma, asymmetric septal hypertrophy (idiopathic hypertrophic subaortic stenosis), concomitant or recent (previous 14 days) monoamine oxidase inhibitor (MAOI) therapy, general anaesthesia with halogenated hydrocarbons (particularly halothane), tachyarrhythmias or ventricular fibrillation, and hypersensitivity to ephedrine or other stimulants.

Legal

Australia: Prescription Only (S4) | Canada: Schedule VI | United Kingdom: P | United States: List I OTC

Pharmacokinetics

Bioavailability: 85% | Metabolism: minimal hepatic | Excretion: 22 - 99% renal

Pharmacology

NDRA (Norepinephrine-Dopamine Releasing Agent)

Dosages

Chart shows bounded mass ranges in mg. See the table for all doses.

Threshold

Light

Common

Strong

Heavy

Oral

5-10mg

10-20mg

20-30mg

30-50mg

50mg+

Durations

Onset

Duration

After Effects

Oral

5m to 20m

0 to 3

1 to 8